Merck Launches RNA-Particle Rabies Vaccine, Zoetis Deploys AI Diagnostics as Companion Animal Health Market Eyes $51.48 Billion by 2032
China’s 113% pet population surge since 2020, a 39% decline in veterinary antimicrobial use, and back-to-back product launches from Merck, Zoetis, and Boehringer Ingelheim are converging to double a $26.48 billion market within seven years.
The Global Companion Animal Health Market, valued at USD 26.48 billion in 2025, recorded a concentrated burst of innovation activity in early 2024 as three of its dominant players moved simultaneously across vaccines, AI diagnostics, and orthopaedic therapeutics. Merck Animal Health introduced the NOBIVAC NXT rabies portfolio using advanced RNA-particle vaccine technology in June 2024; Zoetis Inc. launched its Vetscan Imagyst AI-powered urine sediment analysis platform in January 2024; and Boehringer Ingelheim rolled out NexGard SPECTRA in India. Maximize Market Research projects the market will reach USD 51.48 billion by 2032, expanding at a 9.87% CAGR – fueled by 398 million pets in the U.S. alone and China’s pet population growth of 113% between 2020 and 2024.
Merck’s RNA-Particle Rabies Vaccine and Zoetis’s AI Diagnostics Platform Redefine Preventive Care
Merck Animal Health launched the NOBIVAC NXT Rabies portfolio in June 2024 – including NOBIVAC NXT Feline-3 and Canine-3 – leveraging RNA-particle technology to enhance immunity and safety in companion animals. The rollout aligns with a 39% decline in veterinary antibiotic use (2022–2024), with pharmaceuticals and vaccines now exceeding 62% of the market. In parallel, Zoetis Inc. integrated AI-driven urine sediment analysis into Vetscan Imagyst, improving diagnostic speed and accuracy as the USD 4.6 billion companion animal diagnostics market grows at ~9% CAGR.
“Merck applying RNA-particle technology to a companion animal vaccine is a platform signal, not just a product launch. It confirms that the investment infrastructure built for human immunology is now being systematically redeployed into veterinary medicine.” — Senior Animal Health Analyst, Maximize Market Research
Boehringer Ingelheim Expands NexGard SPECTRA into India as TheraVet Enters Germany
Boehringer Ingelheim launched NexGard SPECTRA in India in 2024 for dogs aged two months+, targeting region-specific parasitic disease burdens as part of its Asia-Pacific expansion strategy – the fastest-growing region in 2025, led by China, Japan, and South Korea. South Korea’s pet population rose 50% (2020–2025) to 7.5 million, while China grew 113% post policy relaxation. Meanwhile, TheraVet expanded BIOCERA-VET into Germany. Industry R&D spend reached ~7.3% of sales, nearly double manufacturing averages.
“Boehringer’s NexGard SPECTRA launch in India is a long-term market-building bet, not a short-term revenue move. When a market’s pet population grows 113% in four years, the companies that establish brand presence earliest capture the compounding loyalty benefit.” — Market Intelligence Lead, Maximize Market Research
Market Context: $26.48 Billion Base, 398 Million U.S. Pets, and a $103 Billion Annual Spend
Maximize Market Research values the global companion animal health market at USD 26.48 billion in 2025, projected to reach USD 51.48 billion by 2032 at a 9.87% CAGR. The U.S. records ~USD 103 billion in annual pet spending, with 36% allocated to veterinary services and 70% household pet ownership across ~398 million animals. North America leads revenue, while Asia-Pacific is the fastest-growing region. Antimicrobial use declined globally (102 to 97 mg/kg, 2020–2024), though the Middle East saw a 43% increase, highlighting regulatory divergence.